GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Alkermes, Inc. (ALKS) [hlAlert]

Rating:
Average ALKS
down 21.03 %

Alkermes, Inc. (ALKS) downgraded to Average with price target $10 by Caris & Company

Posted on: Wednesday,  Oct 20, 2010  9:25 AM ET by Caris & Company

Caris & Company rated Average Alkermes, Inc. (NASDAQ: ALKS) on 10/20/2010. Previously Caris & Company rated Above Average Alkermes, Inc. (NASDAQ: ALKS)
on 07/14/2010., when the stock price was $12.98. Since then, Alkermes, Inc. has lost 21.03% as of 10/20/2010's recent price of $10.25.
If you would have followed the previous Caris & Company's recommendation on ALKS, you would have lost 21.03% of your investment in 98 days.

Alkermes, Inc. is a biotechnology company that develops innovative medicines designed to yield better therapeutic outcomes and improve the lives of patients with serious disease. Alkermes currently has two commercial products: RISPERDAL CONSTA, the first and only long-acting atypical antipsychotic medication approved for use in schizophrenia, and marketed worldwide by Janssen-Cilag, a wholly owned division of Johnson & Johnson; and VIVITROL the first and only once-monthly injectable medication approved for the treatment of alcohol dependence and marketed in the U.S. primarily by Cephalon, Inc. Alkermes' pipeline includes extended-release injectable, pulmonary, and oral products for the treatment of prevalent, chronic diseases such as central nervous system disorders, addiction and diabetes.

Caris & Company, an investment bank created by a diverse group of leading Wall Street professionals. We are founded on the basic principle that Wall Street requires a different type of organization: One that offers objective, conflict-free research, acute focus on customer service, broad institutional coverage, and an unwavering commitment to increasing the value of our clients' portfolios. Quite simply, our goal is to generate solid investment ideas for our clients. We offer a unique, differentiated, conflict-free research perspective on large, mid, and small capitalization companies in four growth oriented verticals: Health Care, Technology, Energy, and Consumer.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
10/20/2010 9:25 AM Hold
None
10.25 10.00
as of 12/31/2010
1 Week   
1 Month   
3 Months down  -30.03 %
1 YTD down  -21.03 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
7/14/2010 9:25 AM Buy
None
12.98 15.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy